Join us on Saturday 11th May at 5pm for the next in our series of webinars. Dr Vasantha Gowda, consultant in paediatric neurology and neuromuscular …
Spring Webinar – Dr Vasantha Gowda ‘DMD and Emergencies’Read More
26 April 2024 by Lizzie Cox
Join us on Saturday 11th May at 5pm for the next in our series of webinars. Dr Vasantha Gowda, consultant in paediatric neurology and neuromuscular …
Spring Webinar – Dr Vasantha Gowda ‘DMD and Emergencies’Read More
26 April 2024 by Lizzie Cox
For anyone who missed the brilliant webinar hosted by Professor Annemeike Aartsma-Rus from 13th April 2024, this is the recording of her session. She …
26 April 2024 by Lizzie Cox
Andria Papageorgiou, postgraduate research student at The University of Surrey, is inviting you to take part in a 6 week programme for parents/carers …
Take part in a trial programme about behavioural and emotional difficultiesRead More

22 April 2024 by Lizzie Cox
Introducing Our Newest Trustee: Emma Simmonds “On behalf of the Board of Trustees at Action Duchenne, I extend a warm welcometo Emma as our newest …

19 April 2024 by Lizzie Cox
We decided our regular online support groups needed a bit of a re-think. To make sure we’ve got everyone covered, there are now going to be 4 …

28 March 2024 by John Marrin
We stand with the Duchenne community in expressing our disappointment regarding the National Institute for Health and Care Excellence's (NICE) recent …

22 March 2024 by John Marrin
Further to our previous article on the publication of the phase 3 EPIDYS trial positive results for Givinostat, a histone deacetylase (HDAC) inhibitor …
FDA Approves Givinostat for the Treatment of Duchenne Muscular Dystrophy in the USARead More

21 March 2024 by John Marrin
We are thrilled to announce exciting new developments regarding the investigational drug Givinostat, after Italfarmaco S.p.A. announced today that the …

5 March 2024 by John Marrin
PepGen, a biotech company developing innovative oligonucleotide therapies for severe neuromuscular and neurological diseases, has received approval …
PepGen Receives UK CTA Clearance from MHRA to Begin CONNECT2-EDO51 Phase 2 Clinical TrialRead More

29 February 2024 by John Marrin
PTC has provided a community statement regarding the recently decision by the CHMP/EMA to not renew the marketing authorisation for Translarna …
23 February 2024 by Lizzie Cox
Annual General Meeting 2024 The Trustees of Action Duchenne would like to express their gratitude for the continued support from the Duchenne …

16 February 2024 by John Marrin
Sarepta Therapeutics, Inc, today announced the U.S. Food and Drug Administration (FDA) has accepted and filed the company's ‘Efficacy Supplement’ to …
Action Duchenne
2nd Floor
South
One Castle Park
Tower Hill
Bristol
BS2 OJA
0300 102 1762
info@actionduchenne.org
